Your browser doesn't support javascript.
loading
Medicinal (Radio)Chemistry: Building Radiopharmaceuticals for the Future.
Pijeira, Martha Sahylí Ortega; Nunes, Paulo Sérgio Gonçalves; Chaviano, Samila Leon; Diaz, Aida M Abreu; DaSilva, Jean N; Ricci-Junior, Eduardo; Alencar, Luciana Magalhães Rebelo; Chen, Xiaoyuan; Santos-Oliveira, Ralph.
Afiliação
  • Pijeira MSO; Nuclear Engineering Institute IEN Rio de Janeiro Brazil.
  • Nunes PSG; Laboratório Biosintesis P&D Bioengineering São Paulo Brazil.
  • Chaviano SL; Centre Hospitalier de l'Université de Montréal Radiopharmacy Montreal Canada.
  • Diaz AMA; Centre Hospitalier de l'Université de Montréal Radiopharmacy Montreal Canada.
  • DaSilva JN; University of Montreal Radiopharmacy Montreal Canada.
  • Ricci-Junior E; Universidade Federal do Rio de Janeiro Faculty of Pharmacy Rio de Janeiro Brazil.
  • Alencar LMR; Federal University of Maranhão Physics São Luís Brazil.
  • Chen X; Nanyang Technological University Radiopharmacy Singapore Singapore.
  • Santos-Oliveira R; Nuclear Engineering Institute Laboratory of Radiopharmacy and Nanoradiopharmaceuticals Rio de Janeiro Brazil.
Curr Med Chem ; 2023 Aug 18.
Article em En | MEDLINE | ID: mdl-37594105
ABSTRACT
Radiopharmaceuticals are increasingly playing a leading role in diagnosing, monitoring, and treating disease. In comparison with conventional pharmaceuticals, the development of radiopharmaceuticals does follow the principles of medicinal chemistry in the context of imaging-altered physiological processes. The design of a novel radiopharmaceutical has several steps similar to conventional drug discovery and some particularity. In the present work, we revisited the insights of medicinal chemistry in the current radiopharmaceutical development giving examples in oncology, neurology, and cardiology. In this regard, we overviewed the literature on radiopharmaceutical development to study overexpressed targets such as prostate-specific membrane antigen and fibroblast activation protein in cancer; ß-amyloid plaques and tau protein in brain disorders; and angiotensin II type 1 receptor in cardiac disease. The work addresses concepts in the field of radiopharmacy with a special focus on the potential use of radiopharmaceuticals for nuclear imaging and theranostics.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article